Sermorelin / Ipamorelin

The blend pairs two GH-secretagogue peptides with distinct receptor targets, both of which have been characterized by structural biology. The GHRH-derived component engages the GHRH receptor (GHRHR), a class B1 (secretin-family) G-protein-coupled receptor expressed on anterior-pituitary somatotrophs. Cryo-EM work (Zhou et al., 2020) reported the structure of the human GHRHR–GHRH–Gₛ complex, mapping peptide contacts across the receptor transmembrane bundle, extracellular loops, and extracellular domain; this structure is used as a reference framework for interpreting how GHRH fragment analogs engage the receptor. The ghrelin-receptor agonist component targets GHS-R1a (the ghrelin receptor), a class A GPCR coupled through Gq and the phospholipase C/inositol-trisphosphate/intracellular-calcium pathway. Separate structural work (Yang et al., 2021) characterized the human GHS-R1a in complex with ghrelin and a synthetic secretagogue agonist, resolving the ligand-binding pocket and key hydrophobic receptor residues involved in agonist recognition. Together, these two cryo-EM studies supply molecular-level reference structures for interpreting how each component of the blend engages its respective GPCR target.

The foundational pharmacological characterization of the ghrelin-receptor agonist component was carried out in in vitro and in vivo preclinical systems. Raun and colleagues (1998) examined GH release from primary rat anterior-pituitary cells and in anesthetized-rat and conscious-swine models, using pharmacological profiling — including a GHRH-receptor antagonist and comparisons with other growth-hormone-releasing peptides — to establish GHS-R1a as the relevant target. A central focus of that characterization was receptor selectivity: whether the peptide engaged additional anterior-pituitary axes, including adrenocorticotropic-hormone secretion, across a range of experimental conditions. The study framed the compound as a selective GH-secretagogue probe, distinguishing its profile from related peptides that engaged multiple pituitary hormones. Assay endpoints consisted of plasma measurements of GH, ACTH, and other pituitary hormones in the rat and swine model systems.

Human-focused research on this compound class has examined growth-hormone-axis biomarkers as endpoints. A retrospective analysis (Pastuszak et al., 2017) reviewed records from adult men receiving growth-hormone secretagogue combinations that included a GHRH analog, using serum IGF-1 as the primary biomarker endpoint and examining how the concurrent hormonal environment — including estrogen status — influenced those IGF-1 measurements. The study design illustrates how GHRH-analog-based combination regimens are monitored in endocrine research: blood-based hormone assay as a surrogate of axis activity. Earlier pituitary-function research examined GHRH(1-29) in older adults, using 24-hour growth-hormone secretion profiles and serum IGF-1 as research endpoints to characterize somatotropic-axis activity. A review by Walker (2006) discussed the GHRH(1-29) class in the context of pituitary-axis research, noting a mechanistic distinction from exogenous growth-hormone administration related to the preservation of hypothalamic and somatostatin-mediated feedback — a distinction relevant to research designs that probe axis physiology under more naturalistic conditions.

Beyond the GH axis, the ghrelin-receptor agonist component has been investigated in gastrointestinal physiology models. Beck and colleagues (2014) reported a registered Phase 2, double-blind, placebo-controlled clinical study (NCT00672074) of intravenous administration in patients following abdominal surgery, examining gastrointestinal-motility endpoints including time to first tolerance of solid food and tolerability measures. This study design reflects the broader research interest in GHS-R1a as a target in GI-motility investigation, consistent with the established role of ghrelin-pathway signaling in gastric emptying and gut motility. The inclusion of a ghrelin-receptor agonist in a postoperative-ileus clinical research context illustrates that this compound class is studied across settings beyond the somatotropic axis, and that registered clinical designs for the receptor class encompass GI-focused measurement endpoints.